期刊文献+

多西紫杉醇与卡培他滨联合化疗治疗复发转移性乳腺癌疗效观察 被引量:1

Efficacy observation of docetaxel combined with capecitabine in treatment of breast cancer
下载PDF
导出
摘要 目的:探讨多西紫杉醇与卡培他滨联合化疗治疗复发转移性乳腺癌的疗效,为临床治疗提供参考。方法:对本院2009年2月~2011年1月收治的25例乳腺癌患者均采用多西紫杉醇与卡培他滨联合化疗的治疗方案,观察患者的疗效。结果:25例患者中CR2例(8.0%),PR6例(24.0%),SD10例(40.0%),PD7例(28.0%),总有效率为32.0%。19例患者出现骨髓抑制现象,17例出现恶心、呕吐,9例患者出现口腔黏膜炎,13例患者脱发。结论:多西紫杉醇联合卡培他滨治疗复发转移性乳腺癌患者有较好疗效,不良反应较轻,经治疗很快恢复,值得在临床上进一步观察应用。 Objective: To investigate the efficacy of docetaxel combined with capecitabine in the treatment of breast cancer, and provide a reference for clinical treatment. Methods: Twenty five cases of breast cancer patients in our hospital from February 2009 to January 2011 were treated with docetaxel combined with capecitabine, the efficacy were observed. Results: In 25 cases of patients, there were 2 cases (8.0%) of CR, 6 cases (24.0%) of PR, 10 cases (40.0%) of SD, 7 cases (28.0%) of PD, the total effective rate was 32.0%. The bone marrow suppression were in 19 cases, nausea, vomiting were in 17 cases, oral mucositis were in 9 cases, hair loss were in 13 cases. Conclusion: Efficacy of docetaxel combined with capecitabine in treatment of breast cancer is better, patients recovery quickly after treatment and its side effects is less, it is worthy for further clinical application.
作者 何捷
出处 《中国当代医药》 2012年第1期47-48,共2页 China Modern Medicine
关键词 多西紫杉醇 卡培他滨 乳腺癌 联合化疗 Docetaxel Capecitabine Breast cancer Chemotherapy
  • 相关文献

参考文献6

  • 1沈镇宙,张亚伟.乳腺癌外科治疗的回顾和展望[J].中国实用外科杂志,2000,20(1):39-40. 被引量:133
  • 2丁江华,龚升平.卡培他滨联合多西紫杉醇节拍化疗治疗转移性乳腺癌临床研究[J].安徽医药,2009,13(11):1393-1395. 被引量:9
  • 3Gliick S,McKenna EFJr, Royce M.XeNA:capecitabine plus docetaxel,with or without trastuzumab,as preoperative therapy for early breast cancer[J]. Int J Med Sci,2008,5(6):341-346.
  • 4Blum JL,Jones SE,Buzdar AU,et al.Muhicenter phase Ⅱ study of xeloda (capecitabine)in taxena-refractory metastatic breast cancer[J].J Cancer, 2001,92(7): 1759-1768.
  • 5Yardley DA.Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes[J].Clin Breast Cancer,2008,8(6): 487-492.
  • 6Sehuller J,Cassidy J,Dumont E,et al.Preferential activation of eapecitabine in tumor following oral administration in eolorectal cancer patients[J]. Cancer Chemother Pharmacol,2000,45:291.

二级参考文献16

  • 1Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy[ J]. Cancer J,2001,7 (5) :427 - 36.
  • 2Reichardt P, VonMackwltz G, Thuss -tience PC, et al. Muhicenter phase- II study of oral capcitabine (Capecitabine)in patients with metastatic breast cancer relapsing after treatment with taxane - containing therapy[ J]. Ann 0ncol,2003,14 (8) : 1227 - 33.
  • 3O' Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline - pretreated patients with advanced breast cancer. Phase Ⅲ trial resuits[ J]. J Clin 0ncol,2002,20(12) :2812 -23.
  • 4Rocca A, Dellapasqua S, Pietri E, et al. Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc) :Evidence of activity of an antiangiogenic treatment [ J ]. J Clin Oncol, 2007,25 (18S) : 11501.
  • 5Sliva OE, Lopes G, Morgensztern D, et al. Split, low - dose docetaxel and low - dose capecitabine is an active regimen in metastatic breast cancer with minimal toxicity [ J ]. J Clin Oncol, 2006,24 ( 18S ) : 10618.
  • 6Blum JL, Jones SE, Buzdar AU, et al. Muhicenter phase II study of capecitabine in paclitaxel- refractory metastatic breast cancer[ J]. J Clin Oncol, 1999,17 (2) :485 - 93.
  • 7Hanspreet K, Thomas Budd. Metronomic therapy for Breast Cancer [ J]. Current Oncology Reports,2004,6 ( 1 ) :49 - 52.
  • 8Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy:changing the paradigm that more is better[J].Current Oncology,2009,16(2) :7 - 15.
  • 9Silva OE, Lopes G, Morgensztern D, et al. Split, low - dose docetaxel (D) and lowdose capecitabine (C)is an active regimen in meta- static breast cancer with minimal toxicity[ J]. J Clin 0ncol,2006,24 (18S) :10618.
  • 10Silva OE, Lopes G, Morgensztem D, et al. A phase II trial of split, low - dose docetaxeland low - dose capecitabine : a tolerable and efficacious regimen in the first - line treatment of patients with HER2/ Neunegative metastatic breast cancer [ J ]. Clin Breast Cancer, 2008,8(2) :162 -7.

共引文献140

同被引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部